EXHIBIT 99.1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the ordinary shares of Adaptimmune Therapeutics, a public limited company incorporated under the laws of England and Wales, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

 

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

 

Dated this 9th day of May, 2022.

 

PFM Health Sciences, LP   PFM Health Sciences GP, LLC
     
By: PFM Health Sciences GP, LLC,   By: /s/ Darin Sadow
  its general partner     Darin Sadow, Authorized Signatory
     
By: /s/ Darin Sadow    
  Darin Sadow, Authorized Signatory    
     
PARTNER Asset MANAGEMENT, LLC   BRIAN D. GROSSMAN
     
By: PFM Health Sciences GP, LLC,   By: /s/ Darin Sadow
  its manager     Darin Sadow, attorney-in-fact
     
By: /s/ Darin Sadow    
  Darin Sadow, Authorized Signatory